跳至主要内容
临床试验/NCT00000921
NCT00000921已完成2 期

A Phase II, Randomized, Placebo-Controlled Study of the Immunologic and Virologic Effects of Prednisone on HIV-1 Infection

National Institute of Allergy and Infectious Diseases (NIAID)18 个研究点 分布在 1 个国家目标入组 118 人开始时间: 1996年8月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
118
试验地点
18

研究概览

简要总结

The purpose of this study is to see if it is safe and effective to give prednisone to HIV-infected patients.

Prednisone is a corticosteroid, a hormone produced by the body that inhibits immune cell responses. Prednisone may be able to lower the level of HIV in the body (viral load) by reducing the number of cells that HIV can infect. At the same time, prednisone may be able to increase CD4 cell counts (cells of the immune system that fight infection).

详细描述

By inhibiting cellular activation, corticosteroids such as prednisone may inhibit HIV expression and reduce the population of potentially infectable cells. Furthermore, no studies have been performed to systematically evaluate immune function in prednisone-treated, HIV-infected patients or the immune mechanisms that may facilitate increases in CD4+ cell number. This study explores this issue.

Patients are separated into 2 arms according to whether or not they are currently receiving a protease inhibitor (PI) as part of their antiretroviral (ARV) therapy regimen (PI vs no PI therapy). Arm I: Current stable ARV therapy plus prednisone for 8 weeks, followed by 4 weeks at half the prior dose, then a 2-week taper. Arm II: Current stable ARV therapy plus prednisone placebo for 12 weeks.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •You may be eligible for this study if you:
  • •Are HIV-positive.
  • •Have a CD4 cell count of 200-600 cells/mm3 within 30 days of study entry. (This study has been changed. You now must have a CD4 cell count of 200-700 cells/mm3 within 45 days of study entry.)
  • •Have had your viral load measured within 30 days of study entry.
  • •Have been on stable anti-HIV therapy with at least two anti-HIV agents for at least 12 weeks, and you intend to remain on this therapy during the study.
  • •Are at least 18 years of age.
  • •Agree to abstain from sex or use effective methods of birth control during the study and for 30 days after.

排除标准

  • •You will not be eligible for this study if you:
  • •Abuse alcohol or drugs or have a serious psychological condition.
  • •Are allergic to prednisone or other corticosteroids.
  • •Have a history of opportunistic (AIDS-related) infections, including cytomegalovirus (CMV), Mycobacterium avium complex (MAC), or Kaposi's sarcoma (KS).
  • •Have a history of a serious medical condition, including heart problems, tuberculosis (TB), cancer, diabetes, or osteoporosis.
  • •Are being treated for herpes at study entry.
  • •Have received certain medications, including blood pressure medication.
  • •Are pregnant or breast-feeding.

研究者

研究点 (18)

Loading locations...

相似试验